Probiotics in the management of atopic eczema

E. ISOLAURI, T. ARVOLA*, Y. SÜTAS, E. MOILANEN† and S. SALMINEN‡

Department of Paediatrics, University of Turku, *Department of Paediatrics, Tampere University Hospital, †Department of Pharmacology, Medical School, University of Tampere and Department of Clinical Chemistry, Tampere University Hospital, ‡Department of Biochemistry and Food Chemistry, University of Turku, Finland

Summary

Background Over the last two decades the incidence of allergic diseases has increased in industrialized countries, and consequently new approaches have to be explored.

Objective The potential of probiotics to control allergic inflammation at an early age was assessed in a randomized double-blind placebo-controlled study.

Methods A total of 27 infants, mean age 4.6 months, who manifested atopic eczema during exclusive breast-feeding and who have had no exposure to any infant or substitute formula were weaned to probiotic-supplemented, Bifidobacterium lactis Bb-12 or Lactobacillus strain GG (ATCC 53103), extensively hydrolysed whey formulas or to the same formula without probiotics. The extent and severity of atopic eczema, the growth and nutrition of infants, and concentrations of circulating cytokines/chemokines and soluble cell surface adhesion molecules in serum and methyl-histamine and eosinophilic protein X in urine were determined.

Results The SCORAD score reflecting the extent and severity of atopic eczema was 16 (7–25) during breast-feeding, median (interquartile range). After 2 months, a significant improvement in skin condition occurred in patients given probiotic-supplemented formulas, as compared to the unsupplemented group; $\chi^2 = 12.27, P = 0.002$. SCORAD decreased in the Bifidobacterium lactis Bb-12 group to 0 (0–3.8), and in the Lactobacillus GG group to 1 (0.1–8.7), vs unsupplemented 13.4 (4.5–18.2), median (interquartile range), in parallel with a reduction in the concentration of soluble CD4 in serum and eosinophilic protein X in urine.

Conclusion The results provide the first clinical demonstration of specific probiotic strains modifying the changes related to allergic inflammation. The data further indicate that probiotics may counteract inflammatory responses beyond the intestinal milieu. The combined effects of these probiotic strains will guide infants through the weaning period, when sensitization to newly encountered antigens is initiated. The probiotic approach may thus offer a new direction in the search for future foods for allergy treatment and prevention strategies.

Keywords: allergic inflammation, atopy, breast-feeding, food allergy, infants, probiotics

Clinical and Experimental Allergy, Vol. 30, pp. 1604±1610. Submitted 26 January 2000; revised 13 April 2000; accepted 27 April 2000.

Introduction

Probiotics, defined as live microbial food ingredients beneficial to health [1], are normal commensal bacteria of the healthy human gut microflora. The most frequently used genera are lactobacilli and bifidobacteria, and the best-documented current therapeutic application is in the prevention and treatment of diarrhoeal diseases [2,3]. The clinical effects have been explained by promotion of gut barrier functions: normalization of increased intestinal permeability [4] and altered gut microecology [5] and enhancement of intestinal IgA responses [6]. The strains selected for the study, Bifidobacterium lactis Bb-12 and Lactobacillus

Correspondence: E. Isolauri, Department of Paediatrics, University of Turku, 20520 Turku, Finland.
strain GG (ATCC 53103), have both proved safe at an early age [2,3].

Recent epidemiological and experimental studies have demonstrated an inverse association between infections and atopy and their cross-regulatory properties on T-helper responder phenotype [7,8]. Beneficial interactions between microbes and allergic host may also arise from the control of allergic inflammation, a decisive factor in the propagation of sensitization to atopic disease [9,10]. Confrontation with microbial antigens begins in the gastrointestinal tract with the establishment of the indigenous microflora. Normal microflora impacting on the mucosal surface has profound effects on the immunological development of the host [11]; such early and constant microbial stimulus may outweigh that of occasional infections. Indeed, the potential of specific strains of microflora to modulate the immune responses to dietary antigens and to balance the generation of proinflammatory and anti-inflammatory cytokines has been demonstrated in vitro [12–14].

Gut microflora as an endogenous defence mechanism may be amenable to therapeutic exploitation to affect allergic inflammation particularly during the weaning period, when sensitization to newly encountered antigens is initiated. Therefore, to evaluate whether the documented immunomodulatory effects of probiotics provide clinical benefit, we assessed in a randomised double-blind placebo-controlled trial the effects of probiotic bacteria in young infants with atopic eczema, frequently the initial manifestation of allergy.

Methods

Subjects

We selected 27 infants from a group of 100 with early onset atopic disease. They fulfilled the Hanifin criteria for atopic eczema in children [15]. Additional inclusion criteria were that the eczema had begun during exclusive breast-feeding and that the patients had had no exposure to any infant formula or substitute formula before enrolment, and that they tolerated the assigned formulas. In selected infants, atopic eczema began at 1.6 (1.3–2.0) months of age, mean (95% confidence interval, CI). Gastrointestinal symptoms, including vomiting, loose stools and diarrhoea, occurred additionally in 15 (56%) cases. In most cases (82%) there was a positive history of atopic diseases in first-degree family members. They were enrolled at weaning, at a mean age of 4.6 months, when they were still fully breastfed.

At enrolment, serum total IgE concentration (Phadebas IgE Prist, Pharmacia, Uppsala, Sweden) was 7 (IQR 0–20) kU/L. A positive (≥ 0.4 kU/L) radioallergosorbent assay (Pharmacia) for egg, cow milk and wheat was demonstrated in 16%, 11% and 4% of the patients, respectively, and skin prick test reactivity [16] to egg, cow milk and wheat in 15%, 8% and 15%, respectively.

All families gave written informed consent to participate. The Tampere University Hospital Committee on Ethical Practice had approved the study.

Design

In this randomized double-blind study, the patients were divided into three groups; two were weaned to a probiotic-supplemented extensively hydrolysed whey formula (PeptiDuttieli, Valio Ltd, Helsinki, Finland) and one to the same formula without probiotics. The strains, Bifidobacterium lactis Bb-12 (Christian Hansen A/S, Hørsholm, Denmark) and Lactobacillus GG (Valio Ltd, Helsinki, Finland), were selected in view of their documented safety and efficacy in controlling acute infantile diarrhoea. On the basis of previous clinical [2,3] and colonization studies demonstrating colonization even in patients with diarrhoeal disease [5,17], the concentrations of probiotic bacteria in the formulas ranged from 3 × 10⁸ (Lactobacillus GG) to 1 × 10⁹ (Bifidobacterium lactis Bb-12) colony-forming units (cfu)/g.

An independent microbiologist controlled the formulas for the respective bacteria using the standard plate counts method.

Outcome measures

Primary outcome measures were the extent, severity and subjective symptoms (pruritus and sleep loss) of atopic eczema. Secondary measures were the serum concentrations of soluble cell surface molecules and cytokines/chemokines and urinary concentrations of methyl-histamine and eosinophilic protein X (EPX).

Of these markers, granulocyte macrophage-colony stimulating factor (GM-CSF), soluble intercellular adhesion molecule 1 (sICAM-1), tumour necrosis factor-α (TNFα) were selected to evaluate the inflammatory state, and soluble CD4 (sCD4), soluble CD8 (sCD8), IL-2 soluble receptor α (IL-2 sRα) to reflect T-cell-related inflammatory state [18–21], and RANTES (Regulated upon Activation, Normal T-cell Expressed and Presumably Secreted) and monocyte chemotactic protein-1 (MCP-1) to evaluate mast cell activity in circulation. Transforming growth factor-β1 (TGF-β1) and IL-1 receptor antagonist (IL-1ra) were assessed in serum samples to evaluate the reactive anti-inflammatory state in the circulation. Urinary EPX has been purported to be a marker of eosinophilic inflammatory activity and the urinary metabolite of histamine, methylhistamine, a marker of early allergen-induced responses [22,23].
**Evaluation of atopic eczema**

The severity of atopic eczema was assessed by the SCORAD method, established by the European Task Force on Atopic Dermatitis [24], prior to introduction of the randomly assigned formula, and 2 months and 6 months later. The extent was estimated using the rule of nines, the intensity being the sum of the scores for erythema, oedema and/or papules, excoriation, lichenification and dryness. The subjective manifestations, including pruritus and sleep loss, were assessed from parents’ estimations. SCORAD was obtained with the calculation: Extent/5 + 3.5 × intensity + subjective score.

**Immunological evaluation**

Venous blood and urine samples were taken prior to introduction of the randomly assigned formula and 2 months later and kept at –70°C until analysis. An enzyme-linked immunosorbent assay method was applied using commercial kits of sCD4, sCD8, IL-2sRα, sICAM-1, IL-1ra, RANTES, MCP-1; purchased from RD Systems, Minneapolis, MN, USA, and TNF-α, GM-CSF, TGF-β1; purchased from Genzyme, Cambridge, MA, USA. Methyl-histamine and EPX concentrations in diluted urine samples were measured by radioimmunoassay using reagents from Pharmacia & Upjohn Diagnostics, Uppsala, Sweden. Results are expressed as μg of methyl-histamine or EPX per mmol of creatinine in the urine sample.

**Growth and nutrition**

The nutrient intake was evaluated as described elsewhere [25]. In brief, parents kept home records of nutrient intake for 3 consecutive days before and after the intervention, quantities of solid and liquid ingested being estimated with household measures. Calculations of nutrient intake were made with the AIVO computer program, compiled from Finnish nutrient databases [26] and manufacturers’ data. Weighing the infant quantified breast milk intake. Length and weight were measured with a recumbent infant length board and an electronic scale before introduction of the extensively hydrolysed formulas, and 2 and 6 months later. For further characterization of nutritional status, serum concentrations of albumin, pre-albumin, urea and alkaline phosphatase were determined during follow-up.

**Statistical analysis**

Data are given as means with 95% CI or medians with interquartile range (IQR). The Kruskal–Wallis test compared the SCORAD scores in the study groups. To avoid repeated pairwise testing, this test was also used for comparison between the groups of changes from baseline in immunological variables. In a case of statistical significance, Wilcoxon signed-rank test was used in pairwise comparisons. ANOVA was used to compare formula intake and nutritional variables between the groups and the χ² test for comparison of the proportions of infants with clinical improvement in the three groups. Spearman’s rank correlation coefficient was used to determine the degree and significance of association between urinary methyl-histamine and EPX concentrations and the severity of atopic eczema (SCORAD scores).

**Results**

**The effect of probiotics on atopic eczema**

SCORAD during breast-feeding was 16 (7–25), median (IQR). After weaning to a tolerated extensively hydrolysed formula, the scores decreased, reflecting an improvement in skin condition in terms of extent, intensity and subjective assessment, but the response differed between the study groups (Fig. 1). The improvements were confined to the probiotic-supplemented groups, where a significant change in the SCORAD scores was seen at 2 months’ evaluation in 9/9 of the patients receiving Bifidobacterium lactis Bb-12, 9/9 in the Lactobacillus GG group as compared to 4/9 in patients receiving the unsupplemented extensively hydrolysed formula; \( P = 0.002 \). At this stage, the SCORAD scores in the Bifidobacterium lactis Bb-12 group had decreased to 0 (0–3.8), and in the Lactobacillus GG group to 1 (0.1–8.7), vs 13.4 (4.5–18.2) in the unsupplemented group; \( P = 0.01 \). After 6 months the median (IQR) SCORAD score was 0 (0–6.6) in all groups alike.

**The effect of probiotics on immunological variables**

In patients receiving Bifidobacterium lactis Bb-12 and Lactobacillus GG, but not in the unsupplemented group, the concentration of serum sCD4 decreased after 2 months’ intervention (Table 1); the Kruskal–Wallis test demonstrated a statistically significant difference in the changes from baseline between the three study groups (\( P = 0.005 \)). The concentrations of sCD8 and IL2sRα in sera tended to decline in all three groups after consumption of the assigned formulas. Serum TGF-β1 concentration was again modified by probiotics (\( P = 0.007 \), Kruskal–Wallis test), but the response diverged in patients given a probiotic strain (Table 1): it decreased in those receiving Bifidobacterium lactis Bb-12 (\( P = 0.04 \)), whereas it tended to increase with Lactobacillus GG (\( P = 0.07 \)). The serum concentrations of IL-1ra, TNFα, GM-CSF, sICAM-1, RANTES and MCP-1α were not modified by probiotics.
Before intervention, the concentration of EPX in urine correlated significantly with the SCORAD scores during breastfeeding (rho = 0.53, P = 0.01) but that of methylhistamine showed no correlation (rho = 0.24, P = 0.27). A significant reduction in the urinary EPX was detected in the probiotic-supplemented groups, *Bifidobacterium lactis* Bb-12 (P = 0.01) and *Lactobacillus* strain GG (P = 0.04); Fig. 1 insert.

Growth and nutrition

At enrolment, breast milk comprised the source of nutrition; 108 (97–120) mL/kg, mean (95% CI). After 2 months, the groups were comparable with respect to formula intake, mean (95% CI): in patients receiving the unsupplemented extensively hydrolysed formula 75 (63–88) mL/kg, in patients receiving *Bifidobacterium lactis* Bb-12 73 (63–88) mL/kg and in patients receiving *Lactobacillus* GG 76 (70–82) mL/kg; P = 0.96. The consumption equalled 53 (38–68%), 52 (42–62)% and 56 (50–62)% of the total energy intake of the infants in the respective treatment groups; P = 0.85. After 6 months, consumption of formulas had decreased to 63 (56–69) mL/kg, i.e. 42 (37–47) kcal/kg [177 (156–199)] kJ/kg]. A parallel increase in solid food intake was recorded: 64 (59–70) kcal/kg [270 (245–294)] kJ/kg], this comprising 60 (56–65)% of total energy intake.

During the 6 months’ follow-up, the mean intake of probiotics was 3–8 × 10^10 cfu/d. No significant decreases were observed in the numbers of the bacteria in the test formulas during storage.

The growth of the patients in all study groups was normal during the entire follow-up period. The mean (95% CI) length-for-age standard deviation scores before, after 2 months’ and after 6 months’ intervention were –0.04 (–0.41–0.33), –0.11 (–0.46–0.22) and 0.0 (–0.43–0.42), respectively. Before intervention, the mean (95% CI) serum albumin, pre-albumin, alkaline phosphatase concentrations were within the normal range: 41 (40±42) g/L, 0.14 (0.14±0.15) g/L and 672 (564±780) U/L, respectively, and no differences were observed between the groups during follow-up. The serum urea concentration tended to be low during breastfeeding, 1.98 (1.79–2.16) mmol/L, mean (95% CI); normal range 2.0–6.0 mmol/L. Probiotic supplementation was shown at the 2 months’ evaluation to have benefited this nutritional variable: in patients receiving *Bifidobacterium lactis* Bb-12 4.1 (3.4–4.7), *Lactobacillus* GG 3.3 (2.7–3.7) vs. unsupplemented 2.9 (2.1–3.7) mmol/L, mean (95% CI); P = 0.02. At 6 months, the concentration was normal, 4.0 (3.5–4.4) mmol/L, in all study groups alike.

Discussion

The human intestinal microflora is a complex and metabolically active ecosystem. Its establishment is a systematic process, which continues through the first years of life [27]. This is a critical period, when immune responsiveness to ubiquitous antigens is consolidated. The notion that the microflora, and thus probiotics, may have a role in immune priming of the infant to the extrauterine world is based on the recent demonstration in experimental animals that the gut-associated lymphoid tissue evolves through bacterial colonization [28]. The capacity to produce IgA-secreting cells increases progressively in response to intestinal antigenic stimulation, particularly from the gut microflora [29]. Importantly, bacterial colonization appears mandatory for the generation of oral tolerance instead of sensitization to dietary antigens [30]. Thus qualitative
differences in the composition of the gut microflora affect the immunological homeostasis of the host.

The criteria for a probiotic include that the strain be of human origin, be safe in human use and stable to acid and bile, and that it adhere to the intestinal mucosa [1]. The genera used in the present study, lactobacilli and bifidobacteria, evince a natural association with the human mucosal surfaces of the mouth, gastrointestinal tract and genitourinary tract.

Probiotic bacteria have been shown to promote the intestine’s endogenous host defence mechanisms [1±6], which may be amenable to therapeutic exploitation to control early allergic inflammation, a key to preventing the progression of atopic symptomatology. Indeed, central to the relevance of our approach was that this extreme population is at highest risk of multiple food allergy [25] and asthma [31], while concomitantly not yet having developed the relevant mature immunological memory [7]. Our strategy, based on the consumption of specific microorganisms of the healthy gut microflora, is an important extension of the observation that there is counterregulation of atopic-type immune responses by specific microbial antigens [7,8] and of the recent epidemiological demonstration of an inverse association between infections at an early age and atopy later in life [32,33].

Probiotics were here shown to reduce the extent, severity and subjective symptoms of atopic eczema in young infants. In unsupplemented group, control of atopic eczema was achieved by 6 months, while in the probiotics-supplemented after 2 months’ therapy, indicating earlier control of allergic inflammation. In sensitized infants, dietary antigens evoke inflammatory reaction, which impairs the intestine’s barrier function, leading to aberrant antigen uptake, imbalance of the intestinal microflora and release of pro-inflammatory cytokines, which further perpetuate the inflammatory response and barrier dysfunction [34]. In unbalanced microflora, pathogens are abundantly present, leading to abrogation of the interaction maintained in health between the microflora and the immune system; strong inflammatory response may then also be directed to the microflora bacteria [35]. Probiotics have been shown to alleviate intestinal inflammation, as measured by faecal TNFα [36], and to promote the gut barrier functions, as directly evaluated by macromolecular absorption [4], and to normalize altered gut microecology [1]. As indicated here, probiotics may counteract inflammatory changes beyond the intestinal milieu.

In addition to diminishing clinical signs and symptoms of atopic eczema, alleviation of allergic inflammation was supported by the reduction of sCD4 in serum and EPX in urine of patients receiving Bifidobacterium lactis Bb-12 and Lactobacillus GG. Soluble CD4 has been found to alleviate intestinal inflammation, as measured by faecal TNFα [36], and to promote the gut barrier functions, as directly evaluated by macromolecular absorption [4], and to normalize altered gut microecology [1]. As indicated here, probiotics may counteract inflammatory changes beyond the intestinal milieu.

### Table 1

The concentrations, median (interquartile range), of soluble CD4 (sCD4), soluble CD8 (sCD8), IL-2 soluble receptor α (IL-2sRα) and transforming growth factor-β1 (TGF-β1) in sera of atopic patients before (before) and after 2 months’ (after) consumption of the randomly assigned extensively hydrolysed whey formula (EHF), unsupplemented or supplemented with Bifidobacterium lactis Bb-12 or with Lactobacillus strain GG.

<table>
<thead>
<tr>
<th></th>
<th>EHF</th>
<th>EHF + Bifidobacterium lactis Bb-12</th>
<th>EHF + Lactobacillus strain GG</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before</td>
<td>After</td>
<td>Before</td>
</tr>
<tr>
<td>sCD4 pg/mL</td>
<td>5118 (4735–5555)</td>
<td>4456 (3482–5235)</td>
<td>5601 (5092–6189)</td>
</tr>
<tr>
<td>sCD8 ng/mL</td>
<td>15 (10–17)</td>
<td>10 (9–12)</td>
<td>12 (11–17)</td>
</tr>
<tr>
<td>IL-2sRα pg/mL</td>
<td>4307 (3789–4429)</td>
<td>3605 (2927–3981)</td>
<td>3605 (2927–4885)</td>
</tr>
<tr>
<td>TGF-β1 ng/mL</td>
<td>75 (63–82)</td>
<td>75 (67–87)</td>
<td>76 (75–82)</td>
</tr>
</tbody>
</table>

*P < 0.05, in comparisons to the baseline measurements (in case of overall statistically significant difference between groups in Kruskal±Wallis test).
symptoms particularly in atopic patients with eosinophilic esophagitis and gastroesophageal reflux disease. Indeed, as both processes, reduction of soluble CD4, a marker of T-cell activation, and increase of TGF-β1, mediating IgA production and low-dose oral tolerance induction [38,39], are involved in suppression of inflammatory response, it is not surprising that the clinical outcome was indistinguishable.

Our results constitute the first clinically documented demonstration of a possible role for specific microbes in controlling allergic inflammation. Investigations are in progress to determine the interaction between the gut microbiota and the immunological homeostasis of the host. An improved understanding of the immunomodulatory mechanisms accredited to different microbes, their combinations and growth factors may offer novel disease-specific probiotic functional foods, also carrying implications for future allergy prevention and treatment strategies.

Acknowledgements

We thank Tuija Poussa for able statistical consultations. This study was funded by the Academy of Finland, European Union (FAIR CT96–1028), and the Medical Research Funds of Tampere and Turku University Hospitals.

References


